| Sign In to gain access to subscriptions and/or personal tools. |
The effects of pre-treatment with enalapril maleate on scopolamine-induced cognitive deficits in healthy volunteersDepartment of Clinical Neuroscience, Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
Department of Clinical Neuroscience, Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
Department of Clinical Neuroscience, Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
Department of Clinical Neuroscience, Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
Department of Clinical Neuroscience, Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK Two studies were undertaken to investigate the effects of acute (Study 1) or repeated (Study 2) administration of the angiotensin converting enzyme (ACE) inhibitor enalapril on the cognitive deficits produced by scopolamine administration in volunteers. Enalapril at doses between 2.5 and 10.0 mg p.o. produced virtually complete blockade of plasma ACE activity. However, it did not influence the effects of scopolamine on a variety of cognitive tasks, including tests of memory, attention and sedation.
Journal of Psychopharmacology, Vol. 5, No. 3,
228-233 (1991) |
|||